Peroxisome proliferator-activated receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3950-3957

  Yin, Yuzhi ^a   Russell, Robert G ^a   Dettin, Luis E ^a   Bai, Renkui ^a   Wei, Zhi Liang ^b   Kozikowski, Alan P ^b   Kopleovich, Levy ^c   Glazer, Robert I ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ESTROGEN RECEPTOR ALPHA; GESTAGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CELL DIFFERENTIATION; CELL SURVIVAL; CHOLESTEROL TRANSPORT; FATTY ACID OXIDATION; FEMALE; GENE EXPRESSION SYSTEM; GLUCOSE UTILIZATION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TARGET CELL; TUMOR DIFFERENTIATION;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, DUCTAL; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; OXAZOLES; PPAR DELTA; PPAR GAMMA; THIAZOLES; TYROSINE;

EID: 18144384743     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3990     Document Type: Article

References (71)

1. Clarke SD, Thuillier P, Baillie RA, Sha X. Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors. Am J Clin Nutr 1999;70:566-71.
2. Kopelovich L, Ray JR, Glazer RI, Crowell JA. Peroxisome proliferator-activated receptor modulators as chemopreventive agents. Mol Cancer Ther 2002;1:357-63.
3. Stoll BA. Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention. Eur J Cancer Prev 2002;11:319-25.
4. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-4.
5. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
6. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A 2001;98:2598-603.
7. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat Med 2004.
8. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B. Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002;10:721-33.
9. Zeng X, Xu H, Park B-K, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Cα. Cancer Res 2002;62:3538-43.
10. Xie Z, Zeng X, Waldman T, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates β-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res 2003;63:5370-5.
11. Di-Poi N, Michalik L, Tan NS, Desvergne B, Wahli W. The anti-apoptotic role of PPARβ contributes to efficient skin wound healing. J Steroid Biochem Mol Biol 2003;85:257-65.
12. Lee CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 2003;302:453-7.
13. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998;4:1053-7.
14. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998;4:1058-61.
15. Saez E, Rosenfeld J, Livolsi A, et al. PPAR{γ} signaling exacerbates mammary gland tumor development Genes Dev 2004;18:528-40.
16. Saez E, Olson P, Evans RM. Genetic deficiency in Pparg does not alter development of experimental prostate cancer. Nat Med 2003;9:1265-6.
17. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 1999;3:799-804.
18. Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999;94:1113-20.
19. Ikezoe T, Miller CW, Kawano S, et al. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res 2001;61:5307-10.
20. Takada I, Yu RT, Xu HE, et al. Alteration of a single amino acid in peroxisome proliferator-activated receptor-α (PPAR α) generates a PPARδ phenotype. Mol Endocrinol 2000;14:733-40.
21. Pighetti GM, Novosad W, Nicholson C, et al. Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res 2001;21:825-9.
22. Suh N, Wang Y, Williams CR, et al. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-3.
23. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000;92:418-23.
24. Camp HS, Li O, Wise SC, et al. Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 2000;49:539-47.
25. Clay CE, Namen AM, Atsumi G, et al. Magnitude of peroxisome proliferator-activated receptor-γ activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med 2001;49:413-20.
26. Davies GF, Khandelwal RL, Wu L, Juurlink BH, Roesler WJ. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-γ (PPARγ)-independent, antioxidant-related mechanism. Biochem Pharmacol 2001;62:1071-9.
27. Nakashiro K, Begum NM, Uchida D, et al. Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor γ. Oral Oncol 2003;39:855-61.
28. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-8.
29. Wei ZL, Kozikowski AP. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor δ. J Org Chem 2003;68:9116-8.
30. Cardiff RD, Anver MR, Gusterson BA, et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000;19:968-88.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
32. Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI. Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 2002;21:198-206.
33. Aldaz CM, Liao QY, LaBate M, Johnston DA. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 1996;17:2069-72.
34. Li B, Kittrell FS, Medina D, Rosen JM. Delay of dimethylbenz[a] anthracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein. Mol Carcinog 1995;14:75-83.
35. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50.
36. Berger J, Wagner JA. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol Ther 2002;4:163-74.
37. Smalley M, Ashworth A. Stem cells and breast cancer: a field in transit. Nat Rev Cancer 2003;3:832-44.
38. 1 cell cycle regulators. Biochem Biophys Res Commun 2001;286:916-22.
39. Wang C, Fu M, D'Amico M, et al. Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-activated receptor γ-dependent repression of cyclin D1. Mol Cell Biol 2001;21:3057-70.
40. Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB. Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002;277:31781-8.
41. Suchanek KM, May PJ, Robinson JA, et al. Peroxisome proliferator- activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog 2002;34:165-71.
42. Bruemmer D, Berger JP, Liu J, et al. A non-thiazolidinedione partial peroxisome proliferator-activated receptor γ ligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol 2003;466:225-34.
43. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52.
44. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998;1:465-70.
45. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4:1046-52.
46. Varley CL, Stahlschmidt J, Smith B, Stower M, Southgate J. Activation of peroxisome proliferator-activated receptor-γ reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol 2004;164:1789-98.
47. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA 1997;94;237-41.
48. Hazra S, Xiong S, Wang J, et al. Peroxisome proliferator-activated receptor γ induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004;279:11392-401.
49. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloprateinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003;89:1817-21.
50. Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 2003;63:1906-13.
51. Hromas R, Cripe L, Hangoc G, Cooper S, Broxmejer HE. The exodus subfamily of CC chemokines inhibits the proliferation of chronic myelogenous leukemia progenitors. Blood 2000;95:1506-8.
52. D'Amico M, Wu K, Di Vizio D, et al. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res 2003;63:3395-402.
53. Iyengar P, Combs TP, Shah SJ, et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 2003;22:6408-23.
54. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W, Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 1996;137:354-66.
55. Grimaldi PA. The roles of PPARs in adipocyte differentiation. Prog Lipid Res 2001;40:269-81.
56. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61.
57. Possali L, Rocchetti R, Talevi S, et al. The role of peroxisome proliferator-activated receptor γ in bladder cancer in relation to angiogenesis and progression. Gen Pharmacol 2000;35:269-75.
58. Fauconnet S, Lascombe I, Chabannes E, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator- activated receptors in bladder cancer cells. J Biol Chem 2002;277:23534-43.
59. Yamakawa K, Hosoi M, Koyama H, et al. Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000;271:571-4.
60. Belanger AJ, Lu H, Date T, et al. Hypoxia up-regulates expression of peroxisome proliferator-activated receptor γ angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor tα. J Mol Cell Cardiol 2002;34:765-74.
61. Panigrahy D, Singer S, Shen LQ, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002;110:923-32.
62. Kahn J, Mehraban F, Ingle G, et al. Gene expression profiling in an in vitro model of angiogenesis. Am J Pathol 2000;156:1887-900.
63. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-21.
64. Lee SJ, Nathans D. Proliferin secreted by cultured cells binds to mannose 6 phosphate receptors. J Biol Chem 1988;263:3521-7.
65. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002;173:219-38.
66. Volpert O, Jackson D, Bouck N, Linzer DI. The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis. Endocrinology 1996;137:3871-6.
67. Parfett CL. Induction of proliferin gene expression by diverse chemical agents that promote morphological transformation in C3H/10T1/2 cultures. Cancer Lett 1992;64:1-9.
68. Butt AJ, Dickson KA, McDougall F, Baxter RC. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 2003;278:29676-85.
69. Callahan R, Raafat A. Notch signaling in mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia 2001;6:23-36.
70. Benaud C, Dickson RB, Thompson EW. Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 1998;50:97-116.
71. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003;100:2645-50.